Loading
An academic trials group based in Porto Alegre that runs cancer studies across Brazil and Latin America, from drug trials to the cohorts that showed how breast cancer care differs between public and private patients.
The Latin American Cooperative Oncology Group is an academic clinical research group whose investigators give its address as Porto Alegre. ClinicalTrials.gov lists 47 studies with LACOG as lead sponsor when checked on 3 November 2026: phase 2 drug trials (among them datopotamab deruxtecan with carboplatin and pembrolizumab for untreated brain metastases from lung cancer, NCT06822543), one phase 3 trial of anthracycline and taxane sequencing in locally advanced HER2-negative breast cancer (NCT04540692), and many cohort and registry studies that describe how cancer presents and is treated in Brazil and Latin America.
The best known of those cohorts is AMAZONA III (GBECAM 0115, NCT02663973), run with the Brazilian breast cancer study group GBECAM and the Ministry of Health: 2,950 women with newly diagnosed invasive breast cancer at 23 Brazilian sites from 2016 to 2018. Women treated in the public system were diagnosed at stage III more often than privately insured women (33.5 against 14.7 per cent) and waited longer from diagnosis to first treatment (median 56 against 34 days).
OnCo could not reach the group's own website on 3 November 2026, so its founding date and membership are not given here.
Carlos Barrios is the most visible Latin American voice in global breast cancer trials and a founder of the region's cooperative group LACOG.
A breast cancer oncologist in Porto Alegre who led the AMAZONA III study, which measured how much later Brazilian women in the public health system are diagnosed and treated than women with private insurance.
Brazil's 60-day law sets a ceiling, and this is a measurement of how the public system performs against it for one cancer. Knowing where the delay sits is what lets a patient or a health service push on it.
In Brazil the same disease is found later in the public system, which treats most women. The authors note that Brazil's cancer registries are limited in number and quality, which is why a cohort like this is needed to see it.
Shares HR-positive / HER2-negative breast cancer and the tag cooperative-group.
Shares HR-positive / HER2-negative breast cancer and the tag cooperative-group.
Shares HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag cooperative-group.
Shares Cervical cancer and the tag cooperative-group.
Shares Prostate cancer, Non-small-cell lung cancer and the tag cooperative-group.
Shares Non-small-cell lung cancer and the tag cooperative-group.
Shares HR-positive / HER2-negative breast cancer and the tag cooperative-group.
Shares Cervical cancer and the tag cooperative-group.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/